	US 11,993,588 B2
	Crystalline forms of a MAGL inhibitor
Cheryl A. Grice, San Diego, CA (US); Todd K. Jones, San Diego, CA (US); Kurt G. Grimm, San Diego, CA (US); Jacqueline Lorayne Blankman, San Diego, CA (US); and Channing Rodney Beals, San Diego, CA (US)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. Lundbeck A/S, Valby (DK)
Filed on Sep. 8, 2021, as Appl. No. 17/469,535.
Application 17/469,535 is a continuation of application No. 16/349,142, granted, now 11,142,517, previously published as PCT/US2017/061875, filed on Nov. 15, 2017.
Claims priority of provisional application 62/423,126, filed on Nov. 16, 2016.
Prior Publication US 2022/0235037 A1, Jul. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/10 (2006.01)

CPC C07D 403/10 (2013.01) [C07B 2200/13 (2013.01)]

6 Claims

1. A crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate free base, wherein the crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate free base has an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 7.8° 2-Theta, 12.0° 2-Theta, 18.5° 2-Theta, 19.0° 2-Theta, 19.6° 2-Theta and 21.2° 2-Theta.